Buy, Sell or Hold: Medtronic Inc (MDT-N) — Stock Predictions at Stockchase

skip to content

NYSE:MDT

123.09

1.44 (1.18%) 1d

Showing 1 to 15 of 90 entries

«
‹
1
2
3
4
5
›
»

Next Page

BUY

They report Thursday. Boring, but he predicts stellar numbers. Their medical devices are being installed in record numbers post-pandemic. There's a lot of pent-up demand from all these delayed surgeries.

biotechnology / pharmaceutical

BUY on WEAKNESS

Allan Tong’s Discover Picks Up 14.68% since August 18, 2020 MDT was trading at $101. It has since climbed as high as $122.15, but now lockdowns are delaying elective surgeries, and the stock is starting to wobble around $117. Keep an eye on this, because continuing lockdowns and a general market pullback would make this a buy again. Right now, MDT is pricey, trading at a 43x PE, which is nearly double from last April and the highest level in 12 months. Its divvy pays nearly 2%. Analysts target the stock at $129.26, based on 17 buys and three holds. Read 2 Successful Past Picks: Nuvei & Medtronic for our full analysis.

biotechnology / pharmaceutical

TOP PICK

The global leader in med-tech space by revenue. It has increased dividends for 42 consecutive years. 9.4% total return for the last 5 years. Benefits from the aging demographics. Does a lot of tuck in acquisitions. The top line is growing at 9% in the last 10 years. (Analysts’ price target is $128.84)

biotechnology / pharmaceutical

BUY

Likes this medical device-maker. They presented at today's JPMorgan's healthcare conference. The stocked slipped 1% today after the company trimmed organic growth forecast this quarter because the explosion of Covid cases is forcing the postponement of medical procedures. This happened at a previous conference, so he's not surprised. The Covid issue is temporary and meanwhile more people will get vaccinated that will unleash pent-up demand for MDT's devices.

biotechnology / pharmaceutical

BUY

There is a backlog of elective surgeries. This is a good area of the industry to be in. She chose JNJ-N but MDT-N is a good candidate too.

biotechnology / pharmaceutical

BUY

A large medical tech company, one of the largest in that field. It is a nice industry that he likes. They deliver consistent earnings growth. It is more of an oligopoly market. It could be a core holding in a portfolio to get medical technology exposure. He holds BSX-N, however.

biotechnology / pharmaceutical

BUY on WEAKNESS

Sales could be light, because people may be light, because it makes medical devices and people are postponing operations due to Covid. If MDT gets hit, buy it, because a Covid vaccine is coming. It reports Tuesday.

biotechnology / pharmaceutical

BUY

A premier medical device-maker. Their most recent report beat the street. These medical stocks sold off during the lockdown over fears that surgeries would halt indefinitely, but those fears and sell-offs were overdone.

biotechnology / pharmaceutical

BUY

Allan Tong’s Discover Picks The Medtronic Stock is one of the largest medical device companies on the globe. It pays a decent dividend of 2.3%, which has grown in the last 28 straight years. MED trades at a 22x PE and has a price target of $110.17, $8 higher than Monday’s trade. MED beat three of its last four quarters, missing its last reported EPS of 68 cents by 10 cents. It boasts a profit margin of 16.56%. Read Cybersecurity Stocks, Clean Energy Stocks and Medical Device Stocks: Little-Known Picks for our full analysis.

biotechnology / pharmaceutical

TOP PICK

One of the largest device companies in the world. There's a lot of pent-up demand coming for surgeries. It was $120, and now it's around $100. Should see $120 again. Yield is 2.29%. (Analysts’ price target is $110.50)

biotechnology / pharmaceutical

BUY

Medtronic vs. Stryker Both make medical devices, and have been impacted by COVID, because operations have been delayed. But now those ops are coming back. She owns JNJ instead, which includes a medical devices division. Unless there's a sharp uptick in the virus that shuts down hospitals again, demand for medical devices should rise and should even ramp in the near future.

biotechnology / pharmaceutical

HOLD

It has grown its dividend 28 consecutive years. Not all of its businesses will be firing. It will not get the same lift because it is not 100% exposed to COVID-19. After COVID the whole diagnostic space will be an interesting one. The dividend is probably relatively safe.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Oct 02/19, Up 7%) They reported today and miss expectations. It's a big global company. There's global demand for their medical devices; in Asia, for instance, there's rising heart disease. So, Medtronic can fulfill this demand.

biotechnology / pharmaceutical

BUY

A large cap diversified company. Their recent acquisition to get into the robotic spine is positive. It has everything for tools and devices, including pacemakers. The chart looks great. This would be the one to own in the space.

biotechnology / pharmaceutical

BUY

Good company. Biggest product is pacemakers. Trades at 19x earnings. Good stock price stability. Trades attractively against peers. Given the multiple, and predictability of earnings, you should look at a 10% return or greater over time.

biotechnology / pharmaceutical

Showing 1 to 15 of 90 entries

«
‹
1
2
3
4
5
›
»

Next Page

Medtronic Inc(MDT-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 7

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 7

Stockchase rating for Medtronic Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Medtronic Inc(MDT-N) Frequently Asked Questions

What is Medtronic Inc stock symbol?

Medtronic Inc is a American stock, trading under the symbol MDT-N on the New York Stock Exchange (MDT). It is usually referred to as NYSE:MDT or MDT-N

Is Medtronic Inc a buy or a sell?

In the last year, 7 stock analysts published opinions about MDT-N. 7 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Medtronic Inc.

Is Medtronic Inc a good investment or a top pick?

Medtronic Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Medtronic Inc.

Why is Medtronic Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Medtronic Inc worth watching?

7 stock analysts on Stockchase covered Medtronic Inc In the last year. It is a trending stock that is worth watching.

What is Medtronic Inc stock price?

On 2021-10-22, Medtronic Inc (MDT-N) stock closed at a price of $123.09.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc.